Value of early post-operative growth hormone testing in predicting long-term remission and residual disease after transsphenoidal surgery for acromegaly
AuthorsWang, Y. Y.
Trainer, Peter J
Higham, Claire E
Gnanalingham, K. K.
AffiliationDepartments of Neurosurgery, Greater Manchester Neurosciences Centre, Salford Royal Foundation Trust (SRFT),
MetadataShow full item record
AbstractIntroduction: Surgical remission for acromegaly is dependent on a number of factors including tumour size, invasiveness, and surgical expertise. We studied the value of early post-operative growth hormone (GH) level as a predictor of outcome and to guide early surgical re-exploration for residual disease in patients with acromegaly. Methods: Patients with acromegaly undergoing first-time endoscopic transsphenoidal surgery between 2005 and 2015, in 2 regional neurosurgical centres, were studied. Insulin-like growth factor-1 (IGF-1), basal GH (i.e., sample before oral glucose), and GH nadir on oral glucose tolerance test (OGTT) were tested at various time points, including 2�5 days post-operatively. Definition of disease remission was according to the 2010 consensus statement (i.e., GH nadir <0.4 ?g/L during an OGTT and normalized population-matched IGF-1). Forward stepwise logistic regression was used to determine factors associated with remission. Results: We investigated 81 consecutive patients with acromegaly, 67 (83%) of which had macroadenomas and 22 (27%) were noted to be invasive at surgery. Mean follow-up was 44 � 25 months. Overall, surgical remission was achieved in 55 (68%) patients at final follow-up. On univariate analysis, the remission rates at the end of the study period for patients with early post-operative GH nadir on OGTT of <0.4 (N = 43), between 0.4 and 1 (N = 28), and >1 ?g/L (N = 8) were 88, 54, and 20%, respectively. Similar results were seen with basal GH on early post-operative OGTT. On multivariate regression analysis, pre-operative IGF-1 (odds ratio of 13.1) and early post-operative basal GH (odds ratio of 5.0) and GH nadir on OGTT (odds ratio of 6.8) were significant predictors of residual disease. Based on a raised early GH nadir and post-operative MR findings, 10 patients underwent early surgical re-exploration. There was reduction in post-operative GH levels in 9 cases, of which 5 (50%) achieved long-term remission. There was an increased risk of new pituitary hormone deficiencies in patients having surgical re-exploration compared to those having a single operation (60 vs. 14%). Conclusions: An early post-operative basal GH and GH nadir on OGTT are reliable predictors of long-term disease remission. It can be used to guide patients for early surgical re-exploration for residual disease, although there is increased risk of hypopituitarism.
CitationWang YY, Waqar M, Abou-Zeid A, Kearney T, Caputo C, Davis J, et al. Value of early post-operative growth hormone testing in predicting long-term remission and residual disease after transsphenoidal surgery for Acromegaly. Neuroendocrinology. S. Karger AG; 2021.
- Long-term outcomes of transsphenoidal surgery for management of growth hormone-secreting adenomas: single-center results.
- Authors: Asha MJ, Takami H, Velasquez C, Oswari S, Almeida JP, Zadeh G, Gentili F
- Issue date: 2019 Oct 11
- Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors.
- Authors: Babu H, Ortega A, Nuno M, Dehghan A, Schweitzer A, Bonert HV, Carmichael JD, Cooper O, Melmed S, Mamelak AN
- Issue date: 2017 Aug 1
- Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays.
- Authors: Sarkar S, Jacob KS, Pratheesh R, Chacko AG
- Issue date: 2014 Jul
- Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.
- Authors: Freda PU, Wardlaw SL, Post KD
- Issue date: 1998 Sep
- Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
- Authors: Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA
- Issue date: 1996 Oct